SVA merger forms BetaNova to pursue type 1 diabetes cure
BetaNova Biotherapeutics is formed from a merger, combining proprietary cell therapy, gene-editing and implantable device technologies to target a functional cure for type 1 diabetes.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.